🚀 VC round data is live in beta, check it out!
Advicenne Valuation Multiples
Discover revenue and EBITDA valuation multiples for Advicenne and similar public comparables like Celularity, INmune Bio, BioXcel Therapeutics, Mabion and more.
Advicenne Overview
About Advicenne
Advicenne SA is a late-stage biopharmaceutical company. The company is engaged in the development of paediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. Its goal is to improve the lives of patients from early childhood through adulthood.
Founded
2007
HQ
Employees
26
Website
Sectors
Financials (LTM)
EV
$55M
Advicenne Financials
Advicenne reported last 12-month revenue of $8M and negative EBITDA of ($3M).
In the same LTM period, Advicenne generated ($3M) in EBITDA losses and had net loss of ($9M).
Revenue (LTM)
Advicenne P&L
In the most recent fiscal year, Advicenne reported revenue of $6M and EBITDA of ($7M).
Advicenne expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $8M | XXX | $6M | XXX | XXX | XXX |
| Gross Profit | — | XXX | ($1M) | XXX | XXX | XXX |
| Gross Margin | — | XXX | (24%) | XXX | XXX | XXX |
| EBITDA | ($3M) | XXX | ($7M) | XXX | XXX | XXX |
| EBITDA Margin | (43%) | XXX | (127%) | XXX | XXX | XXX |
| EBIT Margin | (40%) | XXX | (182%) | XXX | XXX | XXX |
| Net Profit | ($9M) | XXX | ($7M) | XXX | XXX | XXX |
| Net Margin | (124%) | XXX | (130%) | XXX | XXX | XXX |
| Net Debt | — | — | $17M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Advicenne Stock Performance
Advicenne has current market cap of $35M, and enterprise value of $55M.
Market Cap Evolution
Advicenne's stock price is $2.38.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $55M | $35M | -0.3% | XXX | XXX | XXX | $-0.51 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAdvicenne Valuation Multiples
Advicenne trades at 7.4x EV/Revenue multiple, and (17.0x) EV/EBITDA.
EV / Revenue (LTM)
Advicenne Financial Valuation Multiples
As of April 2, 2026, Advicenne has market cap of $35M and EV of $55M.
Equity research analysts estimate Advicenne's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Advicenne has a P/E ratio of (3.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $35M | XXX | $35M | XXX | XXX | XXX |
| EV (current) | $55M | XXX | $55M | XXX | XXX | XXX |
| EV/Revenue | 7.4x | XXX | 9.7x | XXX | XXX | XXX |
| EV/EBITDA | (17.0x) | XXX | (7.7x) | XXX | XXX | XXX |
| EV/EBIT | (18.3x) | XXX | (5.3x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | (41.1x) | XXX | XXX | XXX |
| P/E | (3.7x) | XXX | (4.7x) | XXX | XXX | XXX |
| EV/FCF | (10.2x) | XXX | (56.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Advicenne Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Advicenne Margins & Growth Rates
Advicenne's revenue in the last 12 month grew by 34%.
Advicenne's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.3M for the same period.
Advicenne's rule of 40 is 19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Advicenne's rule of X is 69% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Advicenne Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 34% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Margin | (43%) | XXX | (127%) | XXX | XXX | XXX |
| EBITDA Growth | (92%) | XXX | (46%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 19% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 69% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 159% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Advicenne Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Celularity | XXX | XXX | XXX | XXX | XXX | XXX |
| INmune Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| BioXcel Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mabion | XXX | XXX | XXX | XXX | XXX | XXX |
| Jiangsu Wuzhong Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Advicenne M&A Activity
Advicenne acquired XXX companies to date.
Last acquisition by Advicenne was on XXXXXXXX, XXXXX. Advicenne acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Advicenne
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAdvicenne Investment Activity
Advicenne invested in XXX companies to date.
Advicenne made its latest investment on XXXXXXXX, XXXXX. Advicenne invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Advicenne
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Advicenne
| When was Advicenne founded? | Advicenne was founded in 2007. |
| Where is Advicenne headquartered? | Advicenne is headquartered in France. |
| How many employees does Advicenne have? | As of today, Advicenne has over 26 employees. |
| Is Advicenne publicly listed? | Yes, Advicenne is a public company listed on Euronext Paris. |
| What is the stock symbol of Advicenne? | Advicenne trades under ALDVI ticker. |
| When did Advicenne go public? | Advicenne went public in 2017. |
| Who are competitors of Advicenne? | Advicenne main competitors are Celularity, INmune Bio, BioXcel Therapeutics, Mabion. |
| What is the current market cap of Advicenne? | Advicenne's current market cap is $35M. |
| What is the current revenue of Advicenne? | Advicenne's last 12 months revenue is $8M. |
| What is the current revenue growth of Advicenne? | Advicenne revenue growth (NTM/LTM) is 34%. |
| What is the current EV/Revenue multiple of Advicenne? | Current revenue multiple of Advicenne is 7.4x. |
| Is Advicenne profitable? | No, Advicenne is not profitable. |
| What is the current EBITDA of Advicenne? | Advicenne has negative EBITDA and is not profitable. |
| What is Advicenne's EBITDA margin? | Advicenne's last 12 months EBITDA margin is (43%). |
| What is the current EV/EBITDA multiple of Advicenne? | Current EBITDA multiple of Advicenne is (17.0x). |
| What is the current FCF of Advicenne? | Advicenne's last 12 months FCF is ($5M). |
| What is Advicenne's FCF margin? | Advicenne's last 12 months FCF margin is (72%). |
| What is the current EV/FCF multiple of Advicenne? | Current FCF multiple of Advicenne is (10.2x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.